KDR and neoplasm: It is well accepted by now that not all patients will achieve benefit from immune-checkpoint inhibition, hence the need for identifying novel approaches [5]; at the same time, previously unappreciated studies on VEGF biology have demonstrated immunomodulatory properties and tumor regression by disrupting the VEGF/VEGFR pathway and now provide the scientific basis for new combinational treatments.